






CHARACTERIZATION AND RAPAMYCIN TREATMENT OF 









A thesis submitted to Johns Hopkins University in conformity with the requirements for 
the degree of Master of Science & Engineering 
 







Laryngotracheal stenosis (LTS) is an unpredictable, dynamic fibrosis which results in 
pathologic tissue buildup in the larynx and trachea resulting in airway narrowing. LTS 
can be caused by prolonged intubation, local trauma, autoimmune disease, radiation 
exposure, or idiopathic reasons. In many cases, LTS causes significant morbidity by 
limiting one’s ability to speak, swallow and breathe, and may even cause mortality; 
however to date, there is no definite treatment to cure LTS.  
 
Defining the cellular metabolism and function of normal and LTS-derived 
laryngotracheal fibroblasts are unclear. Biopsies were obtained from eight patients 
undergoing operative procedures for LTS and biopsies were taken from both “normal” 
and “scar” segments of their trachea. Fibroblast and cancer lines were analyzed in vitro. 
Scar fibroblasts demonstrated increased proliferation rates, larger cellular area and 
increased collagen-1 expression compared to normal. Metabolically, scar fibroblasts 
reveal lower levels of oxidative phosphorylation and a higher ECAR/OCR ratio. Through 
a comparative analysis, scar fibroblasts exhibit a greater reliance on aerobic glycolysis. 
Scar fibroblasts proliferate considerably more than normal cells. Through a comparative 
analysis, we were able to determine that scar fibroblasts exhibit many of the 
characteristics of the Warburg effect. We believe that this discovery may open 
promising opportunities to exploit this phenomenon and prevent the proliferation of LTS 
in patients.   
 
Rapamycin was evaluated as a method to suppress proliferation and metabolism of 
scar fibroblasts in vitro. Rapamycin demonstrated an anti-fibrotic effect by reducing the 
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proliferation, metabolism, and collagen deposition of human LTS fibroblast in vitro. The 
bioenergetic effects of rapamycin demonstrated a significant decrease in oxidative 
phosphorylation of LTS fibroblasts, suggesting a potential mechanism for the reduction 
of proliferation and differentiation. Rapamycin’s anti-fibrotic effects suggest a promising 
adjuvant therapy for the treatment of laryngotracheal stenosis. In addition, rapamycin 
when administered systemically in vivo when compared to PBS and dexamethasone, 
demonstrated a decrease in lamina propria thickness, a sign of decreased LTS. We 
believe that this one day could be translated to human clinical studies in order to 
provide a definitive treatment to a disease that currently has no effective therapy.  
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1.1 Laryngotracheal Stenosis 
Laryngotracheal stenosis (LTS) is a condition that is caused by pathologic fibrotic tissue 
buildup resulting in airway narrowing (Figure 1). LTS has numerous causes including, 
prolonged intubation, trauma, autoimmune disease, radiation, and idiopathic reasons. 
[1] [2] [3] Furthermore, it has been hypothesized that LTS may be the result of sustained 
inflammation that is caused by an abnormal increase in fibroblasts proliferation, 
collagen deposition, and subsequent scar tissue formation. [4] This disease has 
implications on breathing, speech and swallowing, in addition to a significant increase in 
morbidity and greater socioeconomic effects, due to prohibitive treatment costs and 
social effects of the disease. [5] [6] [7] Furthermore, LTS has the potential to progress to 
a stage where a patient may completely loses their airway, and may require an 
emergency tracheostomy, or other highly invasive surgical procedures. In some more 






Figure 1 – Airways compromised by Laryngotracheal stenosis 
(A) Constricted airway due to Laryngotracheal stenosis prior to dilation (B) Tracheal 
airway opened up post-dilation procedure (C & D) Cricotracheal resection specimen 







1.2 Current Therapies and Challenges 
Current methods to combat LTS attempt to bypass the stenosis physically by opening 
the narrowed trachea via invasive surgical procedures including tracheostomy, stents, 
endoscopic scar excision and dilation, and tracheal & cricotracheal resection. [8] [9] [10] 
In conjunction with these procedures, local and systemic steroids and drugs such as 
mitomycin C, antibiotics and anti-inflammatory agents, have been used to slow the rate 
of scar formation. [5] [11] [12] [13] [14] [15] [16] [17] [18] The mechanism which these 
poorly understand therapies work and it should be noted these only serve as a 
temporary means to slow progression and do not treat LTS themselves. More 
fundamental and perhaps even more critical, is the lack of understanding between 





Rapamycin (LC Labs, Woburn, MA) also known as sirolimus, rapamine is a macrocyclic 
antibiotic produced by the bacteria streptomyces hygroscopicus, that functions as an 
immunosuppressive medication. Rapamycin complexes with another protein to inhibit 
the mammalian Target of Rapamycin and prevents activation of lymphocytes and other 
immune cells, thereby inhibiting the normal immune response. [19] [20] [21] It is a Food 
and Drug Administration (FDA) approved drug that is frequently used as an antirejection 
agent for transplants well as in coronary stents to reduce restenosis and accelerated 
arteriopathy. [22] [23] [24] There is also evidence to suggest that rapamycin is effective 
in reducing fibrosis and proliferation in a variety of different cell tissue types including 
dermal, hepatic, and renal fibroblasts. [25] [26] [27]  
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1.4 Dexamethasone  
Dexamethasone (Sigma-Aldrich, St. Louis, MO) is a corticosteroid that is commonly 
used as an anti-fibrotic agent to prevent the spread of fibrosis throughout the body 
including the airway and liver. [28] [29] [30] In the trachea, dexamethasone has been 
used to treat patients with LTS with significant success. [31] Given the positive results 
from dexamethasone, it serves as a strong positive control for in vivo experiments when 
comparing the results of rapamycin.  
 
1.5 Fibrosis 
Tissue injury can result in acute and chronic inflammation which, if expressed over a 
long period of time, can trigger fibrosis. Fibrosis is a dynamic disease process by which 
fibroblast dysfunction, on a cellular level, can eventually lead to organ dysfunction and 
clinical disease. This disease is not limited to a single organ, but can manifest 
throughout parts of the body, most commonly leading to the development of pulmonary 
fibrosis, cardiac fibrosis, or cirrhosis. Regardless of which organ is affected, untreated 






















CHAPTER 2 – VARIATIONS IN NORMAL VERSUS FIBROTIC HUMAN 






The objective of this study is to investigate the variability between fibrotic and normal 
fibroblasts in vitro. Determining the fibroblast’s proliferative rates is critical to 
understanding ways to limit stenosis spread; genetic profiling provides a functional 
difference between the fibroblast types; histo-stereometric measurements provide 
physiological characteristics; while metabolic analysis helps better understand reasons 
behind the abnormal spread of LTS.  
 
2.2 Materials and Methods 
 
2.2.1 Fibroblast Isolation and Culture 
After obtaining approval from the Johns Hopkins University Institutional Review Board, 
biopsies were obtained from eight patients undergoing operative procedures for LTS 
between 2012 and 2015. Informed consent was obtained prior to operation and biopsies 
were taken from both “normal” and “scar” segments of their subglottic trachea. 
Immediately after excision, tissue samples were placed in phosphate buffered saline 
(PBS; Gibco, Grand Island, NY) supplemented with 5% penicillin/streptomycin (Gibco). 
Biopsy specimens were then minced to ~1 mm3 size pieces using a #10 Feather 
disposable scalpel (Graham-Field, Atlanta, GA), cut into a 100 x 20 mm uncoated tissue 
culture plastic petri dishes (Falcon by Corning, Corning, NY) and were grown in 
fibroblast growth medium at 37C in 5% CO2 humidified atmosphere. The fibroblast 
growth medium consists of Dulbecco’s modified Eagle’s medium (Gibco) supplemented 
with 10% fetal bovine serum (Thermo Scientific, Logan, UT), 100U/mL penicillin (Gibco), 
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100ug/mL streptomycin (Gibco), and 1X non-essential amino acids (Gibco). Once cells 
reached confluence, 0.25% Trypsin-EDTA treatment (Gibco) allowed fibroblasts to lift 
from the dishes, at which point cells were re-seeded onto tissue culture plastic flasks 
(BD Biosciences, San Jose, CA) for further expansion. Passage two or three of primary 
fibroblast cell lines were used for all experiments. Besides the cellular proliferation 
studies, cells were harvested on day six for the DNA assay, histological staining and 
PCR whereas cells were harvested on day two for the metabolic studies. Unless 
otherwise noted, cells were seeded at 5x103 cells per well of a 6-well plate (BD 
Bioscience, Franklin Lakes, NJ). 
 
JHU-011 cell line was obtained from the Division of Head and Neck Cancer Research, 
Johns Hopkins University in Baltimore, Maryland and was expanded from a laryngeal 
head and neck squamous cell carcinoma (HNSCC). [33] These cells were utilized for 
metabolic studies because they best exemplified laryngeal cancer of the head and neck. 
However, these cells had high adhesion to tissue culture plastic and were not suitable 
for cell proliferation studies.  
 
HT-1080 cell line is a fibrosarcoma that was developed by American Type Culture 
Collection (Manassas, VA). These cells were used for cell proliferation, PCR and 




2.2.2 Cell Proliferation by Cell Count and DNA Assay 
Once the fibroblast cells and the fibrosarcoma at confluence, they were trypsinized and 
seeded. Cell counts for the respective days were performed in duplicate using a 
hemocytometer.  
 
Cells were enzymatically lysed and DNA assay was performed by fluorescently tagging 
cells using PicoGreen and analyzing them in duplicate per manufacturer’s protocol 
(Invitrogen, Waltham, MA) [34]. The subsequent fluorescence was analyzed with a 
Synergy 2 Microplate Reader (BioTek Instruments, Winooski, VT).  
 
2.2.3 Cellular Histology and Trichrome Staining 
Fibroblasts were grown on microscope cover glass slips (Fisher Scientific, Hampton, 
NH) pretreated with 0.01% gelatin solution. The cells were stained with Masson’s 
Trichrome #HT15 kit (Sigma-Aldrich, St. Louis, MO) in order to visually assess 
differences in collagen deposition between normal and scar fibroblasts. Cover slips with 
cells were dehydrated and mounted onto Superfrost Plus microscope slides (Fisher 
Scientific, Hampton, NH). Microscopic images of stained coverslips were viewed and 
captured using a Zeiss AX10 microscope (Carl Zeiss, Oberkochen, Germany). 
Stereological cellular area measurements were obtained using ImageJ (National 
Institute of Health, Bethesda, MD) in conjunction with a Wacom Tablet (Wacom, Kazo, 
Japan). [35] This experiment was run in triplicate per biological replicate. 
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2.2.4 Gene Expression Analysis by Real-Time Polymerase Chain Reaction 
Fibroblasts and the fibrosarcoma were seeded in 6-well plates (BD Biosciences) at a 
concentration of 20x103 cells per well, and were grown for six days. Cells were then 
harvested and frozen at -80 °C and the RNA was extracted using the RNeasy Micro Kit 
(Qiagen, Valencia, CA). Quantification of the RNA was accomplished using the 
nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham, MA). cDNA synthesis 
was done using the iScript cDNA synthesis kit (BioRad, Hercules, CA). Quantitative 
Real Time PCR (qRT-PCR) was performed using the SYBR Green PCR Mastermix 
(Life Tech, Carlsbad, CA) on the StepOnePlus Real Time PCR System (Life Tech). 
Reaction mixtures were incubated for 10 min at 95°C followed by 40 cycles of 15s at 
95°C, 1 min at 60°C, and finally 15s at 95°C, 1 min at 60°C, and 15s at 95°C. Collagen I 
was used as the target gene and Beta Actin (ACTB) as PCR control. The level of 
expression of the target gene was calculated as 2-ΔΔCt equaling a fold change from each 
sample compared to each patient sets’ respective “normal” fibroblast fold change. When 
assessing fibrosarcoma cells, the cancer cells were compared to an average of all 
patient sets’ “normal” fibroblast fold change. This experiment was run in triplicate. 
 
2.2.5 Cellular Oxygen Consumption Rate 
Functional mitochondrial were analyzed by evaluating the oxygen consumption rate 
(OCR) via a XF24 Flux Analyzer and XF Cell Mito Stress Test (Seahorse Bioscience, 
Billerica, MA). Fibroblasts and the HNSCC were seeded in DMEM at 3x104 cells/well a 
day prior to analysis. During the day of the mitochondrial stress test, the previous media 
was washed twice and exchanged with minimal XF Assay media supplemented with 25 
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mM glucose (Sigma-Aldrich, St. Louis, MO), 1X GlutaMax (Invitrogen, Waltham, 
Massachusetts) and 1X Non-Essential Amino Acids (Invitrogen, Waltham, 
Massachusetts) per the manufacturer’s protocol. The cells were allowed to acclimate for 
an hour at 37°C in a humidified atmosphere without CO2 prior to mitochondrial stress 
test. Oxygen consumption rates are determined by using 10 uM Oligomycin, an ATP 
Coupler, injected at 34 minutes, 4 uM Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone, FCCP, an ATP uncoupler, injected at 72 minutes, 20 
uM Rotenone and Antimycin, mitochondrial inhibitors, injected at 110 minutes. Through 
the metabolic stress test, the Basal Metabolic rate, ATP production and maximal 
respiratory capacity can be elucidated. To ensure that post stress test the number of 
cells had remained the same, a PicoGreen DNA was used to determine that the total 
protein amount to be roughly 10mg per well.  
 
2.2.6 Cellular Extracellular Acidification Rates 
Glycolytic function measurements were analyzed by evaluating the Extracellular 
Acidification Rate (ECAR) using a XF24 Flux Analyzer. The fibroblasts and the HNSCC 
were seeded in DMEM at 4x104 cells/well a day prior to analysis. During the day of the 
glycolytic stress test, the previous media was washed twice and exchanged with 
minimal XF Base glucose-free media without supplements per the manufacturer’s 
protocol. The cells were allowed to acclimate for an hour at 37°C in a humidified 
atmosphere without CO2 prior to mitochondrial stress test. Oxygen consumption rates 
was determined by using 5 mM Glucose, a glycolysis substrate, injected at 34 minutes, 
10 uM Oligomycin, a ATP Synthase Inhibitor, injected at 72 minutes, 2 uM 2-Deoxy-D-
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glucose, a Glycolysis Inhibitor, injected at 110 minutes. Similarly to the oxidative 
phosphorylation test, PicoGreen was used to verify DNA concentration.  
 
2.2.7 Statistical Analysis 
Results are expressed as averages ± standard error of the mean. For cellular area, a 
Mann-Whitney Test and p-value < 0.05 is considered significant. For proliferation, DNA 
assay, metabolic studies, a Wilcox Signed Rank Test and p-values < 0.05 is considered 




2.3.1 Scar fibroblasts showed increased cell proliferation when compared to 
normal 
When cultured and grown under the same conditions in vitro, scar fibroblasts 
demonstrate an increased cell proliferation rate verified through cell counting 
measurements and DNA assay measurements across all five of our patient cell lines 
(Figure 2A). However, both fibroblast cell types grew a far slower rates in comparison 
to the fibrosarcoma (Figure 2B). Furthermore, when analyzing the DNA per cell ratio on 
average for normal and scar were not significantly different at 25.87 ± 16.79 pg/cell and 






Figure 2 - Scar fibroblasts proliferate more than normal fibroblasts 
(A) This figure demonstrates a typical patient set. Although from the initial seeding until 
day 2 there are no significance, the last three days of the study, proliferation has 
resulted in a significant difference of p = 0.002, p = 0.0003, p < 0.0001 for days three, 
four, and five, respectively, between normal and scar cell lines (B) Cell count growth 




2.3.2 Similar Stereometric Measurements verified via Cellular Histology and 
Trichrome Staining 
Scar fibroblasts demonstrate increased cell proliferation compared to normal fibroblasts 
when assessing using microscopy after staining with Masson’s Trichrome to visualize 
cells (Figure 3). Morphology of both normal and scar fibroblasts appears similar with no 
significant differences seen in average cell length. On average, normal and scar cells 






Figure 3 - Morphological and proliferative differences 
Normal (A) and Scar (B) were imagined at Day 6 at 10x Magnification. Scar cells 
demonstrated an increased proliferation and cellular area when compared to Normal 





2.3.3 Collagen Gene Expression elevated in Scar Fibroblasts 
In comparison to normal laryngotracheal fibroblasts, scar fibroblasts demonstrate 
increased collagen gene expression (Figure 4) (p-value = 0.0391). Nevertheless the 
two show far lower than the fibrosarcoma gene expression for Collagen I. 
 
























Figure 4 - Collagen 1 Expression Greater in Scar Fibroblasts 
When normalized to respective Patient Set Normal Laryngotracheal Fibroblasts, Scar 




2.3.4 Cell Oxidative Phosphorylation 
Normal laryngotracheal fibroblasts were more metabolically active in oxidative 
phosphorylation than scar laryngotracheal fibroblasts. Basal metabolism, ATP 
production and maximal respiratory capacity, were significantly different in normal 
fibroblasts than in scar fibroblasts and were elevated when compared to HNSCC 
(Figure 5A, 5B, 5C).  Figure 5D shows a representative graph of a normal and scar 
mitochondrial stress test. Basal metabolism is calculated by taking the difference in the 
peak OCR prior to oligomycin and the base OCR after the rotenone & antimycin 
injection. ATP production is calculated by evaluating the difference pre and post 
oligomycin injection. Maximal respiratory capacity was determined by the difference 
between the peak OCR post-FCCP injection and the base OCR post rotenone & 




Figure 5 - Increased Oxidative Phosphorylation Capacity in Normal Fibroblasts 
Normal fibroblasts show a significant difference in (A) Basal Respiration, (B) ATP 
Production and (C) Maximum Respiration at p = 0.0004, p = 0.0003, p < 0.0001, 
respectively. Panel (D) demonstrates a Mitochondrial Stress Test of a patient set 




2.3.5 Cell Extracellular Acidification 
Normal and Scar fibroblasts demonstrated no significant difference in glycolytic capacity 
(Figures 6A). The difference between the peak ECAR post oligomycin and the base 
ECAR value post 2-DG is used to calculate the glycolytic capacity. Figure 6C 
demonstrates a typical normal and scar glycolytic stress test chart. Furthermore, by 
taking the ratio of glycolytic capacity to maximum respiration from Figure 4, the cellular 
dedication to either metabolic pathway can be elucidated for each cell type (Figure 6B). 
HNSCC demonstrated greater ECAR/OCR than scar but both showed a greater 





Figure 6 - Metabolic Glycolysis Dedication  
Normal and Scar Fibroblasts are similar in (A) Glycolytic Capacity, (B) ECAR/OCR 





The analysis of normal and scar laryngotracheal fibroblasts illustrate proliferative, gene 
expression and metabolism provides a more targeted approach to finding a sustainable 
treatment for LTS. In the eight patients cells used in this study as well as the cancer 
lines, we see that scar fibroblasts proliferate at a significantly faster rate when 
compared to normal fibroblasts, which accounts for the stenosis spread seen in typical 
LTS patients. Nevertheless, both were draft by the proliferative ability of the 
fibrosarcoma. These results are mirrored on a genetic level; scar fibroblasts express 
and deposit collagen at a rate that mirrors clinical effects of collagen deposition at the 
site of stenosis. [26] [36] More surprising was, when analyzing the metabolic differences 
between normal and scar fibroblasts, normal fibroblasts demonstrated, on a 
bioenergetics level, higher mitochondrial metabolism and similar levels of aerobic 
glycolysis which mirrors “the Warburg effect”. 
 
The biological phenomenon termed as the “the Warburg effect” is the observation that 
cells predominantly plant and cancer cells rely primarily on aerobic glycolysis rather 
than oxidative phosphorylation which results in larger lactic acid buildup. [37] [38] 
However, although there is a greater reliance on aerobic glycolysis, mitochondrial 
oxidative phosphorylation seems to remains functional. [39] Albeit cancer or scar cells, 
the reason behind why cells seem to rely on the “Warburg effect” rather than on the 




Oxidative Phosphorylation and glycolytic analysis allows us to determine the 
bioenergetic levels on the cellular level. [40] [41] Our study demonstrates that normal 
fibroblasts consumed more oxygen than scar fibroblasts and HNSCC when concerning 
basal metabolism, ATP production and maximal respiration (Figure 5). However when 
assessing glycolytic metabolism, both normal and scar fibroblasts demonstrate similar 
glycolytic capacity though the HNSCC demonstrated an elevated amount. Interestingly, 
when looking at the ratio between glycolytic capacity and maximal oxidative 
phosphorylation, scar cells demonstrate greater than two-fold increase compared to 
normal fibroblasts which was also demonstrated in the HNSCC (Figure 6). With this 
metabolic data in conjunction with the increased proliferative effects of scar fibroblasts 
in comparison to normal cells, scar cells seem to be undergoing a Warburg-like effect.  
 
It is important to note the limitations of the in vitro study on normal human 
laryngotracheal and scar fibroblasts. In vitro studies are not representative or indicative 
of fibroblasts in vivo but rather serves as a model to help bridge our understanding 
between the differences between the two cell types. In order to prevent changes to the 
primary harvested fibroblasts due to the in vitro environment, we limited the study to 
only passage two or three cells and restricted repeated passaging and freeze-thawing 
of the cells. Nevertheless, these may have had an effect on the cellular phenotype, 
genotype, and behavior. Furthermore, as with any primary harvested cells, there are 
variability between patients in which the cells were derived from. The effects of the 
variability was limited by conducting paired statistical analyses between normal and 
scar fibroblasts to decrease the effects of heterogeneity of the disease process. 
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Nevertheless, we are encouraged by the significant differences between normal and 
scar fibroblasts across the collective patient sets. Cancers cells were added to this 
study to provide a perspective that although normal and scar cells demonstrate 
statistically different features they still are starkly different from the fibrosarcoma and 
HNSCC on my fronts. But more importantly, it demonstrates that scar fibroblasts 
Warburg-like effects though deeper analysis is necessary to determine whether or not 
the cells truly are under the influence of the Warburg effect. Additional studies on the 
genetic level and metabolic studies comparing anaerobic and aerobic glycolysis will be 
needed.  
 
In conclusion, normal and scar fibroblasts show similarities and differences when 
considering proliferation, histo-stereology, genetic variability, and metabolism in vitro. 
By exploiting these differences while keeping in mind their similarities, stenosis and scar 
formation can be targeted more effectively. Furthermore, the Warburg-like effect 
between scar fibroblasts and cancer cells tested shows promise that this may be an 























CHAPTER 3 – RAPAMYCIN INHIBITS HUMAN LARYNGOTRACHEAL STENOSIS 
DERIVED FIBROBLAST METABOLISM IN VITRO1 
  
                                            
1 Permission to reproduce Rapamycin Inhibits Human Laryngotracheal Stenosis–derived Fibroblast 
Proliferation, Metabolism, and Function in Vitro published in American Academy of Otolaryngology – 
Head and Neck Surgery was received by Alexander Hillel, Garret Ma, Idris Samad, and Daryan Namba 
on March 11, 2015. Per the Transfer of Copyright Agreement from the publisher, authors reserve the right 




The aim of this study was to determine whether rapamycin could inhibit human LTS 
fibroblast proliferation in vitro. Fibroblast proliferation is a crucial step for development of 
LTS and collagen is usually implicated in deposition of scar tissue and in fibrosis. 
Therefore, we hypothesized that rapamycin would decrease LTS fibroblast proliferation 
and metabolism, and reduce collagen production. We characterized the effect of 
rapamycin on fibroblasts through growth kinetics, morphology, gene expression, and 
cellular metabolism profile.  
 
3.2 Materials and Methods 
 
3.2.1 Laryngotracheal Fibroblast Isolation and Culture 
Biopsy of human laryngotracheal stenosis was performed during routine suspension 
microlaryngoscopy, bronchoscopy, excision and dilation of subglottic/tracheal stenosis 
in 5 patients. Informed consent was obtained from all patients to join this study, which 
was approved by the Johns Hopkins Institutional Review Board (NA_00078310). 
Immediately after excision, tissue samples were placed in phosphate buffered saline 
(PBS; Gibco Life Technologies by Invitrogen, Grand Island, NY) supplemented with 5% 
penicillin/streptomycin (Gibco). Biopsy specimens were minced and the tissue 
fragments were spread out evenly across uncoated plastic tissue culture flasks (BD 
Biosciences, San Jose, CA) and suspended in fibroblast growth medium at 37C in 5% 
CO2-humidified atmosphere. Fibroblast growth medium consisted of Dulbecco’s 
modified Eagle’s medium (DMEM; Gibco) supplemented with 10% fetal bovine serum 
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(FBS; HyClone by Thermo Scientific, Logan, UT), 100U/mL penicillin (Gibco), 100ug/mL 
streptomycin (Gibco), and 100x non-essential amino acids (NEAA; Gibco). Once cells 
were confluent (between 20-30 days) short-term 0.25% Trypsin-EDTA treatment 
(Gibco) proved effective in releasing only fibroblasts from the flasks, which were then 
plated into new flasks for expansion. Passage two or three of these primary fibroblast 
cell lines were used in the following experiments. To confirm culture of fibroblasts, cells 
were analyzed to be pan cytokeratin negative as well as Mason’s Trichrome stain 
positive. The former of which were compared against known fibroblasts (CRL 2522) and 
fibrosarcoma (HT 1080).  
 
3.2.2 Cell Proliferation by Cell Count and DNA Assay 
After reaching confluence, the adherent LTS fibroblasts were trypsinized and passaged 
into 12-well culture plates (Falcon by BD Biosciences) containing fibroblast growth 
medium, and seeded with 20,000 cells per well. Medium was aspirated and replaced 
daily with the following conditions: 1) control, normal fibroblast growth medium; 2) 
control-vehicle, medium containing vehicle solution, 1% dimethyl sulfoxide (DMSO); 3) 
rapamycin-1, medium containing rapamycin (Sigma-Aldrich, St. Louis, MO) dissolved in 
DMSO at a concentration of 1ng/mL or 10 -10 M; 4) rapamycin-10, medium containing 
rapamycin dissolved in DMSO at a concentration of 10ng/mL or 10-9 M. These 
concentrations were chosen based on previous literature (Poulahan 28, Milani). All 
conditions were grown in triplicate. Cells were harvested on the 6th day of incubation 
and the trypsinized LTS fibroblasts were counted in duplicate. Following, the LTS 
fibroblasts of each well were lysed (10 mM Tris, 1 mM EDTA, 0.1% Triton X-100 and 
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0.1 mg/ml Proteinase K) and DNA concentration was determined using the PicoGreen 
fluorescent method, adapted from the manufacturer’s protocol (Invitrogen Quant-iT 
PicoGreen dsDNA Reagent and Kits Protocol, Molecular Probes P11496). [42] Each 
sample was run in duplicate for the assay. Fluorescence was read using the BioTek 
Synergy 2 Microplate Reader (BioTek Instruments, Winooski, VT).  
 
3.2.3 Gene Expression Analysis by Real Time Polymerase Chain Reaction 
LTS fibroblasts were seeded in 6-well culture plates (Falcon by BD Biosciences) with 
300,000 cells per well and grown in the four medium conditions in duplicate for 6 days. 
The RNeasy Micro Kit (Qiagen, Valencia, CA) was used for RNA extraction of each well 
and the RNA was quantitated using the nanodrop 2000 spectrophotometer (Thermo 
Scientific, Waltham, MA). The iScriptTM cDNA synthesis kit (BioRad, Hercules, CA) was 
used for cDNA synthesis according to the manufacturer’s protocol. Quantitative Real 
Time PCR (qRT-PCR) was performed and monitored using the SYBR Green PCR 
Mastermix (Life Tech, Carlsbad, CA) on the StepOnePlus Real Time PCR System (Life 
Tech). Reaction mixtures were incubated for 10 min at 95°C followed by 40 cycles of 15 
seconds at 95°C, one min at 60°C, and finally 15 seconds at 95°C, one min at 60°C, 
and 15 seconds at 95°C. For each sample, gene expression was corrected against Beta 
Actin level. All samples were run in duplicate. The level of expression of the target gene 
was calculated as 2ΔΔCt as previously described. [43] The control LTS fibroblasts grown 
in normal growth medium were used for reference. Error was calculated by the standard 
deviation of ΔΔCT. [44] The fibrosis marker, Collagen I (Col I) was assessed as 
previously described. [45] 
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3.2.4 Cellular Metabolism using Oxygen Consumption Rate Measurements 
Bioenergetic analysis of oxygen consumption rate (OCR) provides a measurement of 
overall metabolic status of the cell. [46] OCR measurements of LTS fibroblasts were 
completed using a Seahorse XF24 Flux Analyzer (Seahorse Bioscience, Billerica, MA) 
at 4x104 cells per well. They were grown in the four medium conditions for two days 
post seeding with respective medium changed daily. The assay used XF minimal assay 
medium supplemented with 25mM glucose (Sigma), 1X GlutaMax (Invitrogen) and 1X 
Non-Essential Amino Acids (Invitrogen). Prior to the stress test, the cells were washed 
twice with this medium and incubated for one hour at 37°C in a humidified atmosphere 
without CO2. In order to evaluate the mitochondrial respiratory capacity, Oligomycin (an 
ATP Coupler), Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, an ATP 
uncoupler), Rotenone and Antimycin (mitochondrial inhibitors) at 10uM, 4uM and 20uM 
concentration, respectively, were injected into the medium at 34, 72, and 110 minutes 
respectively. PicoGreen DNA quantization assay was performed on each well in order 
to normalize the OCR. DNA content was correlated with the total protein amount per 
well. Basal metabolic rate, ATP production and maximal respiratory capacity were 
measured. 
 
3.2.5 Statistical Analysis 
Results were expressed as averages ± standard error of the mean. Wilcox Signed Rank 







3.3.1 Rapamycin decreases LTS fibroblast proliferation 
Increased rapamycin dosing showed a decreased LTS fibroblast growth rate in all 
patients (Figures 7A, 8A) as well as in the mean (Figure 8B, 8B) for all patients. 
Although in all medium conditions the fibroblasts grew, fibroblasts grown in normal 
medium conditions (mean = 21.9 x 104, STD = 3.9 x 104) grew at a faster rate than the 
fibroblasts grown in DMSO (mean = 17.9 x 104, STD = 5.0 x 104), low-dose (mean = 8.7 
x 104, STD = 2.1 x 104) and high-dose Rapamycin (mean = 4.8 x 104, STD = 1.0 x 104, 
respectively). There was a significant decrease in individual (Figure 7A) and average 
(Figure 7B) LTS fibroblast count cultured with high-dose rapamycin versus DMSO 
vehicle control (p = 0.0007) and normal (p = 0.0007) medium. Low-dose rapamycin also 
demonstrated a significant reduction in fibroblast count when compared to control (p = 
0.0008) and normal (p = 0.0007) medium. Of those same counted fibroblasts, there was 
a significant decrease in DNA concentration of individual (Figure 8A) and average 
(Figure 8B) LTS fibroblasts cultured with high-dose rapamycin versus DMSO vehicle 
control (p = 0.0007) and normal (p = 0.0007) medium. There was also a significant 
difference in DNA concentration for fibroblasts grown in low-dose rapamycin versus 
normal (p = 0.0026) and vehicle medium (p = 0.0015). DNA/cell was not significantly 











Figure 7 - Rapamycin reduces fibroblast count 
Fibroblast count shows a significant reduction in proliferation of laryngotracheal 
stenosis-derived fibroblasts after treatment with low- and high-dose rapamycin in all 5 
patients’ cells (A) compared to normal medium and vehicle medium controls. Average 
cell count (B) shows significance when comparing low-dose Rapamycin compared to 
normal (p = 0.0008) and DMSO (p = 0.0007) controls. Similarly, at high-dose 
Rapamycin there was a significant difference compared to normal (p = 0.0007) and 












Figure 8 - Rapamycin significantly inhibits fibroblast proliferation 
Cell proliferation, measured by DNA assay, demonstrates a significant reduction of 
laryngotracheal stenosis-derived fibroblast proliferation after treatment with low-dose 
rapamycin in all 5 patients’ cells (A) compared to normal and vehicle controls. When 
patient results are averaged (B), fibroblast proliferation shows a reduction with high-
dose rapamycin treatment compared to normal (p=0.0007) medium and DMSO-vehicle 
(p=0.0007) medium controls. Similarly, with low-dose rapamycin treatment, there was a 
significant difference when compared against normal (p = 0.0036) medium and DMSO-




3.3.2 Rapamycin treated fibroblasts demonstrate reduced collagen staining 
LTS fibroblasts were stained with Masson’s Trichrome in order to visualize collagen 
deposition, which stains blue. Histological evaluation of LTS cultured cells after 
treatment of rapamycin showed a decrease in collagen deposition compared to LTS 
cells untreated with rapamycin (Figure 9).  
 
Figure 9 - Morphologic Staining of Drug-Induced Fibroblasts 
Normal (A) and DMSO-vehicle (B) controls demonstrate confluent fibroblasts with 
intense blue staining for collagen by Masson’s Trichrome. There is a reduction in 
fibroblast density and collagen deposition after treatment with low- (C) and high-dose 
(D) rapamycin. All cells grown for 5 days in their respective medium. 
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3.3.3 Rapamycin-treated Fibroblasts have reduced Collagen I Expression 
RT-PCR demonstrated decreased collagen I gene expression in rapamycin treated LTS 
fibroblasts compared to control LTS fibroblasts in all five patients (Figure 10A). The 
average of all five patients also showed a linear trend in which increasing rapamycin 
concentration resulted in a decrease in collagen I gene expression (Figure 10B). There 
was a significant decrease in collagen I expression between LTS fibroblasts grown in 
high dose 10ng/mL rapamycin and in control fibroblast medium (p = 0.0051) and in 
DMSO vehicle medium (p = 0.0093). There was also a significant decrease in collagen I 
expression in LTS fibroblasts grown in low-dose rapamycin versus control (p = 0.0069) 











Figure 10 - Collagen 1 expression is inhibited by rapamycin 
(A) Four of 5 patients demonstrate a significant reduction in Collagen 1 gene expression 
compared to normal medium and vehicle medium controls. (B) When averaged 





3.3.4 Rapamycin decreases the metabolic rate of LTS fibroblasts 
LTS patient-derived fibroblasts were less metabolically active than those grown in 
normal and vehicle medium controls (Figures 11A-D). When averaged together, there 
were significant decreases in basal respiration (Figure 17A), ATP production (Figure 
17B), and maximal respiration (Figure 11C) between LTS fibroblasts treated with high-
dose rapamycin and those cultured in DMSO control (p < 0.05) and fibroblast growth 
medium (p < 0.05). Figure 11D demonstrates the difference in a representative 
patient’s fibroblast oxygen consumption rate between the three medium conditions: 
normal medium control, DMSO control, and high-dose rapamycin. High-dose rapamycin 
decreased the basal metabolic rate (difference in peak OCR prior to Oligomycin and 
lowest OCR post Rotenone/Antimycin) and ATP production (difference in OCR prior to 
and post Oligomycin injection) and decreased maximal respiratory capacity (difference 






Figure 11 - Rapamycin decreases the metabolic rate of LTS fibroblasts 
(A) Mean basal respiration, (B) ATP production, and (C) maximal respiration 
significantly decreased with high-dose rapamycin when compared to normal medium 
and vehicle medium controls. (D) Oxygen consumption rate in representative patient-
derived fibroblasts. Fibroblast cells were seeded in XF96 V3-PS cell culture microplate 
(Seahorse Bioscience) in fibroblast growth medium (FGM), FGM+DMSO, and 
FGM+DMSO+rapamycin(10ng/mL) medium. ATP production, basal and FCCP-coupled 





The results of this in vitro study suggest Rapamycin as a potentially new anti-fibroblast 
therapy for LTS. As shown, we observed a decrease in LTS fibroblast proliferation, 
function, and metabolism with rapamycin. High dose rapamycin demonstrated a 
significant reduction in every outcome measured as compared to vehicle medium and 
normal medium controls in the cells from the 5 patients included in this study. The 
results in these 5 LTS patients are supported by rapamycin’s effect on fibroblasts in 
other organ systems including the lung, liver, and skin by decreasing expression and 
deposition of collagen type I and reducing cell proliferation. [26] [27] [47] This study 
suggests at a potential mechanism by assessing cellular respiration in LTS fibroblasts, 
which showed a reduced mitochondrial metabolic rate after treatment with rapamycin. 
 
Bioenergetic analysis is a novel technique that monitors the oxygen consumption and 
extracellular acidification at a cellular level. [40] [48] [49] The key parameters of basal 
respiration, ATP production, and respiratory capacity may be measured to assess 
mitochondrial metabolism. [40] [49] Importantly, maximal respiratory capacity was 
significantly reduced in rapamycin-treated fibroblasts when non-mitochondrial 
respiration levels were normalized between control and rapamycin-treated groups. As 
seen in this study, the decreased basal respiration decreased ATP production, and 
maximal respiratory capacity after treatment suggests that rapamycin interferes with 





In clinical application for the treatment of LTS we expect rapamycin to exert an 
immunosuppressive effect in addition to antiproliferative effects. Rapamycin has FDA 
approval for immunosuppression to prevent rejection in renal transplant patients and is 
used to coat coronary stents to reduce inflammation and collagen synthesis. [50] [51] 
Furthermore, rapamycin was shown to disrupt mTOR signaling in fibroblasts and 
macrophages and reduce kidney fibrosis. [25] Therefore, we are encouraged by the 
potential of rapamycin treatment as adjuvant therapy for LTS. Modulating the immune 
response may be more effective than current medical therapies. In topical application, 
rapamycin could assist in suppressing the inflammatory response and fibroblast 
proliferation and collagen synthesis seen in LTS while avoiding side effects seen with 
systemic therapy. Ultimately, a rapamycin-eluting stent could direct sustained local 
immunotherapy and anti-fibroblast effect at the area of fibrosis while providing 
mechanical forces on the tracheal wall. Further in vivo investigation is required to 
support our data and hypothesis. 
 
It is an in vitro study of human cells and the behavior of the LTS fibroblasts on culture 
dishes may not be representative of cells in vivo. While only passage 2 and 3 cells were 
used in experiments, the repeated passaging and freeze-thawing may have an effect on 
cell phenotype. Lastly, it is important to note that there was variability among LTS 
fibroblasts in the five different patients (Figures 7A, 8A, 10A, and 11D) with varying 
response to rapamycin appreciated. This patient-specific variability in therapeutic 
response may be encountered with any clinical treatment and may be due to the 
heterogeneity of the disease process or possibly genetic differences in wound healing. 
41 
 
We are encouraged by the significant anti-fibroblast effect of rapamycin when the 
results from the five patients with LTS were averaged.  
 
In summary, rapamycin demonstrated an anti-fibroblast effect by reducing the 
proliferation, metabolism, and collagen deposition of human LTS fibroblast in vitro. The 
bioenergetic effects of rapamycin demonstrated a significant decrease in oxidative 
phosphorylation of LTS fibroblasts, suggesting at a potential mechanism for the reduced 
proliferation and differentiation. Rapamycin’s anti-fibroblast effects combined with its 
immunosuppressive action suggest at a promising adjuvant therapy for the treatment of 
laryngotracheal stenosis. Further studies are underway to compare the metabolism of 
normal and scar fibroblasts isolated from patients with LTS as well as to assess 



















CHAPTER 4 – RAPAMYCIN AS A TREATMENT FOR LARYNGOTRACHEAL 





The aim of this study is to address the in vivo effects of systemic rapamycin in a chemo-
mechanical LTS murine model. Outcome measures include lamina propria thickness 
measurements of histological cuts from sacrificed animals, analysis of gene expression 
through RT-PCR, and post-operative weight and survival studies. The promise of 
rapamycin in vivo opens the potential for use in humans studies and eventually, as a 
potential therapy in the treatment of LTS. [4] 
 
4.2 Materials and Methods 
 
4.2.1 Experimental Design 
This study was approved by the Johns Hopkins University Animal Care and Use 
Committee (MO12M354). 60 10-week old, male C57BL/6 mice (Charles River 
Laboratory) were used in this study. Surgery was performed in groups of thirty. Mice 
were sedated via an intraperitoneal (IP) injection of ketamine at a concentration of 100 
mg/kg, and xylazine at a concentration of 10 mg/kg, prior to bleomycin coated wire-
brush injury to the larynx and trachea to induce chemo-mechanical laryngotracheal 
stenosis (LTS). [4] Post-operatively, the thirty mice were divided into three cohorts of 
10. Each cohort received an IP injection of 100l of their assigned drug therapy. Our 
cohorts received either dexamethasone (Sigma-Aldrich, St. Louis, MO) at a 
concentration of 1 mg/kg, rapamycin (LC Labs, Woburn, MA) at a concentration of 4 
mg/kg or phosphate buffered solution (PBS; Gibco Life Technologies by Invitrogen, 
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Grand Island, NY), once at the time of surgery, and then once every 48 hours, up until 
the 24 hours before sacrifice.  
Each group of thirty mice was pre-designated to be either a one-week, two-week 
or three week cohort. Mice were sacrificed at the appropriate time point, and 
laryngotracheal complexes were dissected out in all groups for histologic analysis or 
RNA extraction for RT-PCR. Peri-operative and post-operative death rates were 
recorded throughout each group, with peri-operative deaths including mice deaths in the 
first 24 hours post-operatively. Our study concluded once we obtained seven specimens 
for each time point and treatment for histological analysis, and three specimens for each 





Figure 12 - Experimental Design 





4.2.2 Histologic Measure Outcome 
The primary outcome measure of this study is lamina propria (LP) thickness. 
Laryngotracheal complexes from each specimen were fixed in 10% formalin, and sent 
to the surgical pathology lab to be embedded in paraffin blocks. Slides were made from 
5-μm-thick sections cut in the axial plane, which were then stained with hematoxiylin-
eosin. Images were taken of these specimens at 5x magnification, and each specimen 
was assessed to measure LP thickness. Each specimen was split into 5 equal 
segments, and the thickest portion of each segment was measured and recorded. 
Measurements were performed from the medial aspect of the tracheal cartilage to the 
basement membrane of the epithelium. Assessment of all images was performed in a 
blinded fashion. Means and standard deviations were calculated from these results.  
 
4.2.3 Mice Weight Outcome 
A secondary outcome measure of this study is mice weight changes. Mice weights were 
recorded prior to surgery, at the time of every injection, and prior to sacrifice. 
 
4.2.4 Statistical Analysis  
 
Statistical significance for lamina propria thickness between groups was determined by 
the Mann-Whitney-Wilcoxon test and defined as P < 0.05. Weight data used a 2-way 
ANOVA test followed by a Tukey test for multiple comparisons and P < 0.05 was 






4.3.1 Measurable Increase in LP Thickness Following Chemomechanical Injury 
Both rapamycin and dexamethasone intraperitoneal injection at one week demonstrate 
significant differences in lamina propria thickness versus the control group at p-value = 




Figure 13 - Lamina Propria thickening 
(A) Lamina propria thickness of PBS IP-injected animals, seven days post-operation (B) 
Lamina propria thickness of dexamethasone IP-injected animals, seven days post-
operation (C) Lamina propria thickness quantification across all animals at seven days 






4.3.2 Survival and Weight Study for three weeks 
At various injections points, weight measurements were recorded per the 
aforementioned methods. Figure 14 shows the changes in weights over the various 
time points. Although of the surviving animals by the end of three weeks, the animals on 
average have recovered their weight, rapamycin and dexamethasone shows significant 
weight recovery from day six through day 16 post-operation when compared to PBS 
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Figure 14 - Percent Weight Recovery Post-Operation 
Rapamycin and dexamethasone demonstrate greater recover post-LTS operation when 
compared to PBS. Both drugs when injected IP are able to almost see full weight 
recovery by two weeks post-operation.  
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PBS vs. Rapamycin 0 -5.786 to 5.786 ns > 0.9999 
PBS vs. Dexamethasone 0 -5.691 to 5.691 ns > 0.9999 
Day 2 
PBS vs. Rapamycin 0.6 -5.186 to 6.386 ns 0.9618 
PBS vs. Dexamethasone -1.78 -7.471 to 3.911 ns 0.7094 
Day 4 
PBS vs. Rapamycin -0.61 -6.658 to 5.438 ns 0.9638 
PBS vs. Dexamethasone -5.06 -11.00 to 0.8809 ns 0.1066 
Day 6 
PBS vs. Rapamycin -1.01 -8.128 to 6.108 ns 0.9299 
PBS vs. Dexamethasone -9.13 -16.25 to -2.012 ** 0.009 
Day 8 
PBS vs. Rapamycin 0.85 -7.202 to 8.902 ns 0.9604 
PBS vs. Dexamethasone -5.34 -13.22 to 2.538 ns 0.2287 
Day 10 
PBS vs. Rapamycin -10.21 -18.48 to -1.940 * 0.0124 
PBS vs. Dexamethasone -8.52 -16.57 to -0.4681 * 0.0362 
Day 12 
PBS vs. Rapamycin -12.4 -20.67 to -4.130 ** 0.0019 
PBS vs. Dexamethasone -9.53 -17.80 to -1.260 * 0.0207 
Day 14 
PBS vs. Rapamycin -11.1 -19.37 to -2.830 ** 0.006 
PBS vs. Dexamethasone -7.32 -15.59 to 0.9502 ns 0.0907 
Day 16 
PBS vs. Rapamycin -10.9 -19.17 to -2.630 ** 0.0071 
PBS vs. Dexamethasone -9.52 -17.79 to -1.250 * 0.0209 
Day 18 
PBS vs. Rapamycin -5.98 -14.83 to 2.873 ns 0.2309 
PBS vs. Dexamethasone -3.47 -12.32 to 5.383 ns 0.5886 
Day 20 
PBS vs. Rapamycin -2.71 -12.46 to 7.036 ns 0.7609 
PBS vs. Dexamethasone -2.62 -12.37 to 7.126 ns 0.7742 
Sacrifice 
PBS vs. Rapamycin -3.78 -13.53 to 5.966 ns 0.595 
PBS vs. Dexamethasone -1 -10.75 to 8.746 ns 0.9626 
51 
 
4.3.3 Survival Study  
Figure 15 shows peri-operative and post-operative deaths for the negative and positive 
control as well as the experimental group. Rapamycin and dexamethasone 
demonstrated higher survivability (p = 0.531, p = 0.226, respectively) when compared to 
the negative control, PBS IP-injection.  
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Figure 15 - Percent Survival by Time Point 
As a percent of the initial animal count, the percent survival is the total number of 





The evaluation of rapamycin in vivo for use in the treatment of Laryngotracheal stenosis 
is critical due to the inability of current treatments to limit the increasingly pervasive 
spread of the disease. From the analysis, we have determined that systemic rapamycin 
demonstrates a decrease in lamina propria thickness when compared to untreated 
cohort in a chemo-mechanical LTS murine model, an increased and quickened weight 
recovery in the chemo-mechanical LTS model compared to untreated cohort, and 
additional survivability.  
 
The translatability of rapamycin to human possibilities is key to the introduction of this 
treatment from benchtop to bedside. Rapamycin is already used as anti-rejection 
medication for organ transplant and is also used on drug eluting stents throughout the 
body to prevent occlusion. Albeit, a systemic dosage or a more localized release of 
rapamycin via a drug-eluting stent, fundamentally rapamycin is an FDA-approved drug 
that has already showed its versatility. The treatment of LTS is merely another use 
amongst the plethora of current indications of the drug.     
 
Although we understand that these results are very promising and may soon be used in 
the treatment of LTS in human patients. It is important to realize the limitations of the 
study. First, the use of an LTS murine model via chemo-mechanical introduction of LTS 
may not reflect the actual disease progress of LTS in humans. In addition, the animal 
model reflects particular aspects of the disease that may not necessarily be reflective in 
human patients. In addition, LTS manifests itself in patients due to various reasons, 
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cancer, prolonged intubation, including idiopathic pathologies. In order to confirm the 
usefulness of rapamycin, it would need to be used in clinical trials. Nevertheless, the 
ability of rapamycin in vivo to limit the progression and even treatment of LTS in the 

























5.1 Impact of Research 
Laryngotracheal stenosis is a disease with no elegant solution. Physical methods using 
tracheostomy, stents, endoscopic scar excision and dilation, and tracheal & 
cricotracheal resection; [8] [9] [10] or use of cocktails of drugs including antibiotics and 
anti-inflammatory agents, have been commonly used to suppress stenosis. However, a 
valid method to tackle the source of the stenosis, on the fibrosis level has yet to come to 
light. The study on rapamycin, an FDA approved drug that is commonly used already on 
drug-eluting stents and as an anti-rejection agent, provides an effective means to 
decrease the proliferation of fibroblasts and subsequently cause animals with LTS to 
recover weight and decrease lamina propria thickness, both indicators for reduced LTS.  
 
In conjunction with the use of rapamycin, understanding the Warburg-like difference 
between normal and fibrotic laryngotracheal fibroblasts is key to exploiting the metabolic 
difference. The analysis of normal and scar laryngotracheal fibroblasts illustrate 
proliferative, genetic and metabolic differences which can provides information on a 
more targeted approach to find a sustainable treatment for LTS. Understanding the 
difference between the two functional types of cells in the tracheal during LTS allows 
the research community a better perspective on how to treat the disease. Thus, this 
serves as a key to effectively treating this socially, physically and emotionally 




5.2 Future Directions 
Continued analysis of the Warburg-like effect using additional HNSCC cell lines, an 
increased genetic panel, and additional patients would be necessary to examine and 
elucidate the greater connection between fibrosis of the trachea and cancer. Though it 
is important to understand the difference between normal and fibrotic fibroblasts, it’s 
perhaps more critical to understand the variations between tracheal cancer and fibrosis. 
From this approach new drugs, therapies that were once unused for the treatment of 
LTS maybe more carefully selected. This could be a method to discover more effective 
treatments for LTS.  
 
For rapamycin, beyond in vivo modeling of the drug to decrease LTS, human trials 
would be necessary to determine the actual validity of the hypothesis that LTS can be 
treated with rapamycin. The genetic variability in humans could alter the effects of the 
drug and its efficacy at treating LTS. Oral dosage of rapamycin both in the short term 
and the long term should be used and compared against a control group to see whether 
or not patients demonstrate decreased stenosis. Pending significant results, it would be 
useful to explore less systemic methods of rapamycin delivery. Given that rapamycin is 
already used in drug-eluting students for the artery, this could be translated to drug 
eluting stents for the trachea. The stent provides a physical barrier against LTS 
thickening and also delivers localized rapamycin to suppress fibroblast proliferation. 
These methodologies, given strong data, can be more effective treatments to this 
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RESEARCH EXPERIENCE 
Johns Hopkins University | Department of Biomedical Engineering                Baltimore, MD 
Graduate Researcher with Dr. Jennifer Elisseeff & Dr. Alexander Hillel        Sep 2013 to Present 
Characterization and rapamycin treatment of laryngotracheal stenosis in vitro and evaluation of the 
efficacy and safety of the drug in a murine LTS model in vivo 
 Hypothesized that Rapamycin induced human tracheal fibroblasts reduce cellular proliferation and 
metabolism, designed experiment to validate hypothesis and reported research results in 
publication in Otolaryngology – Head & Neck Surgery 
 Characterized the significant metabolic, proliferative, morphological and genetic differences 
between normal and fibrotic laryngotracheal fibroblasts in vitro. Results in two submission. 
 Determined the in vivo effects of rapamycin on a laryngotracheal stenosis murine model for 
outcomes in lamina propria thickness and weight/survival changes. Results in submission.  
Evaluation of extracellular matrices (ECM) in vitro and in vivo particularly Chondroitin Sulfate N-
hydroxysuccinimide and Acellular adipose extracellular matrices 
 Investigated the mechanical properties of hydrogels form by crosslinking Chondroitin Sulfate with 
various extracellular matrices; research developed into a paper, in submission. 
 Submitted Innovated New Drug to the Food & Drug Administration (FDA) to begin clinical trials of 
Acellular Adipose ECM. Acceptance, pending.  
Department of Medicine | University of California at Los Angeles                  Los Angeles, CA 
Undergraduate Researcher under Dr. Paul Krogstad         Sep 2011 to Jun 2012 
Modified backbone structure of picornavirus Coxsackievirus B3 plasmid by altering the internal ribosome 
entry site (IRES) and inserting a T7 promoter region to create a more effective and efficient method of 
modifying viruses 
 Incorporated IRES of various known strains of Coxsackievirus and evaluated virulence and 
replication rates  
 Transfected plasmid into HeLa cells, analyzed cytopathic effects and established viral titers via 
plaque assays 
Department of Bioengineering | University of California at Los Angeles           Los Angeles, CA 
Undergraduate Researcher under Dr. James Dunn        Sep 2008 to Jun 2011 
Engineered novel methods to mechanically and chemically enhance nutrient absorption of rats suffering 
from surgically induced short bowel syndrome 
 Mechanically expanded anastomotic jejunum of adult rats to increase villus and crypt surface area 
via spring force 
 Enhanced vascularization of shortened ilium and jejunum with vascular endothelial growth factor 
(VEGF) thereby increasing surface area of nutrient absorption 
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 Established baseline enzymatic activity in unexpanded jejunum and compared villus and crypt 
lengths of unexpanded and expanded small bowel  
Analyzed the effects of varying extracellular matrices and growth factors on the proliferation of primary 
interstitial cells of Cajal (ICC) from neonatal rats and mice 
 Evaluated ICC calcium concentration fluctuation in vitro using fluo-4 acetoxymethyl ester Ca2+ 
indicators 
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Inhibits Human Laryngotracheal Stenosis-derived Fibroblast Proliferation, Metabolism, and Function in 
Vitro. Otolaryngology--head and neck surgery: official journal of American Academy of Otolaryngology-
Head and Neck Surgery. 
 
N.Y. Lei, G. Ma, T. Zupekan, R. Stark, M. Puder, and J.C.Y. Dunn, “Controlled release of vascular 
endothelial growth factor enhances intestinal adaptation in rats with extensive small intestinal resection,” 
Surgery 150(2): 186-190, 2011. 
 
PRESENTATIONS 
G. Ma, J. Yang, M. Wong, M. Ngai, L. Sharpe and J. Reed, “Microfluidic device for routine, high-resolution 
expression profiling of clinical biopsies and single cells”, Podium and Poster Presentations at the UCLA 
Bioengineering Symposium, Los Angeles, California, March 2012.  
 
N.Y. Lei, G. Ma, T. Zupekan, R. Stark, M. Puder, and J.C.Y. Dunn, “Controlled release of vascular 
endothelial growth factor enhances intestinal adaptation in rats with extensive small intestinal resection”, 




Bain & Company               San Francisco, CA 
Associate Consultant              Oct 2015 (start date) 
Abbott Fund | LifeNet International             Bujumbura, Burundi, East Africa 
Consultant                               Jan 2013 to Aug 2013 
 Optimized and reorganized pharmaceutical deliveries to upcountry clinics by 10-fold from 6 to 60 
rural clinics and hospitals 
 Automated ordering and pricing model with Visual Basic that reduced order processing time by 75% 
and drug costs by 5% 
Abbott Laboratories | Vascular                     Temecula, CA 
Quality Engineer for Endovascular Stents        Jun 2012 to Dec 2012 
 Managed technicians from three stent production lines to evaluate risk of defects and examine 
quality of stents in production 
 Raised >$20k for Abbott Employee Giving Campaign as the divisional campaign organizer for 200+ 
employees 
Abbott Laboratories | Global Pharmaceutical Operations                  Waukegan, IL 
Quality Engineer Intern focused on Proprietary Pharmaceutical Products                 Jun 2011 to Sep 2011 
 Developed program written in Visual Basic that streamlined pharmaceutical trend monitoring 
process by 38% 
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Discovery 2 Market | Carey Business School            Johns Hopkins University 
Scientific Advisor              Feb 2015 to Present 
 Advises seven global MBA students at JHU Carey Business School on scientific issues associated 
with Chondroitin Sulfate in a capacity ranging from Innovative New Drug submissions, business 
licensing, market sizing/share and various scientific concepts associated with them product.  
Graduate Representative Organization           Johns Hopkins University 
Treasurer               Sep 2013 to Present 
 Facilitated and allocated around $175k budget that was distributed among 20+ events and clubs 
across the graduate community.  
Johns Hopkins Graduate & Consulting Club            Johns Hopkins University 
Competitor              Sep 2013 to Present 
 Finalist among 60 teams in JHBCC Biotechnology Case Competition held in April 2014; Finalist 
among 67 teams in JHBCC Mini-Case Competition in November 2013; Winner among 10 teams in 
the Deloitte Case Competition held in September 2013 
Biomedical Engineering Society                     University of California at Los Angeles 
President             Sep 2011 to Jun 2012 
 Led meetings of 30+ board members covering budget, event planning and marketing strategies 
 Promoted a community atmosphere for the students in the Department of Bioengineering 
 Coordinated Science Vendor Exposition to bring scientific equipment vendors to UCLA at a 
discounted price 
 Connected Biomedical Engineering Society with numerous biotech and pharmaceutical companies 
in LA-metro area 
Tau Beta Pi, California Epsilon               University of California at Los Angeles 
Biomedical Engineering Society Club Liaison                              Jan 2012 to June 2012 
 Tutored underclassman in engineering subjects including bioengineering, physics, chemistry, and 
calculus 
 Coordinated events between local UCLA chapters of Tau Beta Pi and Biomedical Engineering 
Society  
 Volunteered in an after school program teaching physics at a local low income elementary school 
Department of Medicine               University of California at Los Angeles 
Lecturer                       Sept 2010 to June 2011 
 Taught a college course entitled “AIDS in Sub-Saharan Africa: A Modern Plague” at UCLA for class 
of 20+ students 
 Prepared lectures and facilitated discussions on the economic, political and social impact of HIV 
prevalence 
 Organized guest lectures from leaders in the Global Health Field at UCLA to touch on various 
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of Class)  
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UCLA Engineering scholarship for students that demonstrate exceptional academic and research 
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Engineering Award for Student Welfare (2012) 
Award for outstanding contributions to student welfare through participation in extracurricular activities 
and who have given outstanding service to the campus community  
 
Dean’s List (Awarded four times from 2008-2012) 
Award for students that maintain a 3.70 or above Grade Point Average in a single quarter    
 
 
 
